Measure Biodistribution of Cell Therapies with Spatial Multiomics
Developing immune cell therapies, such as CAR-T, TCR-T, CAR-NK cell, and macrophage therapies, are increasingly being used to treat solid tumors. However, detecting and quantifying these therapies in intact human tumor biopsies remains a challenge.
RNAscope probes can target viral untranslated regions (UTRs) found in all CAR and TCR mRNAs, allowing for the specific detection and quantification of engineered therapeutic cells. RNAscope UTR probes can also be combined with cytokine and chemokine probes to assess immune cell recruitment and activation states in combination with immunohistochemistry (IHC) and immunofluorescent (IF) detection of cell type markers for T cells such as CD3, CD4, and CD8 to monitor cell therapies in post-treatment patient biopsies and preclinical animal models for safety and efficacy.
Highlights
- Visualize and quantify CAR/TCR-T cell infiltration and activation in tumor and non-tumor tissues.
- Measure therapy-induced immune responses and toxicity by visualizing cytokines, T cell markers, or other cell-type markers.
- Evaluate multiomic expression of other RNA and protein targets across multiple types of tissues and animal models.
Detect and Quantify CAR or TCR mRNA in the Tumor Microenvironment (TME)
RNAscope probes are designed to target the 5' or 3' UTR of the CAR vector.
Address Critical Questions in Cell Therapy
New Product! RNAscope Multiomic LS Assay
Combine up to 4 pre-conjugated antibodies with your own primary antibodies and or available conjugated secondary antibodies along with CAR or TCR mRNA RNAscope probes to interrogate the tissue microenvironment.
The RNAscope Multiomic LS assay enables highly sensitive and specific detection of both RNA and proteins in the same tissue section for a true multiomic spatial assay. The pre-conjugated TIL panel is perfect for CAR-T cell therapy assessment in preclinical tissue samples. This assay enables simultaneous detection of up to 6 total proteins and/ or RNA targets with single-cell resolution.
Monitor the Infiltration of CAR- and TCR-T Cells in Tissue
With RNAscope or BaseScope™ ISH probes designed against the 5’ or 3’ UTR from the CAR or TCR vector transcript, engineered T cells can be detected and quantified in the tumor microenvironment (TME) or any other intact tissue. The high sensitivity of the RNAscope assay enables preclinical screening for target antigen expression at the RNA level to avoid adverse effects resulting from on-target/off-tumor activity.
Assess CAR- or TCR-T Cell Functionality and Activation State
The multiplexing capabilities of the chromogenic and fluorescent RNAscope ISH assays enable simultaneous detection of multiple targets on the same slide. CAR or TCR vector transcripts can be co-stained with IFNG and GZMB to assess activation state, or with cell-type markers such as CD3 and CD8 to discern engineered CAR- or TCR-T cells from endogenous T cells.
RNAscope Multiplex Fluorescence ISH/IF assay showing Granzyme B and IFNG expression and CD3+ T cell infiltration in a BCMA+ xenograft tumor treated with anti-BCMA CAR-T cells.
RNAscope Professional Assay Services
Our Professional Assay Services offer you direct access to the developers of RNAscope in situ hybridization (ISH) technology. Accelerate your journey in target validation, preclinical, and clinical development with our promise to provide consistent and trustworthy data to drive your projects forward.
Get Started Today. Speak to a Specialist.
